federal_register: 00-10166
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00-10166 | Prospective Grant of Exclusive License: Second Generation Monoclonal Antibodies, and Humanized Carcinomas | Notice | This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Patent Applications S/N 07/073,685, filed on July 15, 1987, and S/N 07/547,336 (FWC of 07/07,3,685), filed on July 20, 1990, both entitled "Second Generation Monoclonal Antibodies Having Binding Specificity to TAG-72 and Human Carcinomas and Methods for Employing the Same" and now U.S. Patent 5,512,443 which issued on April 30, 1996; and U.S. Provisional Patent Applications S/N 60/106,534, filed on October 31, 1998, and S/N 60/106,757, filed on November 2, 1998, both entitled "Variants of Humanized Anti-Carcinoma MAb CC49", and PCT Patent Application PCT/ US99/25552 (based upon S/N 60/106,534 and 60/106,757) filed on October 29, 1999, entitled "Variants of Humanized Anti-Carcinoma Monoclonal Antibody CC49" to IDEC Pharmaceutical Corporation of San Diego, California. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory will be worldwide and the field of use may be limited to anti-TAG-72 monoclonal antibodies, including fragments, components, constituents and/or humanized variants thereof, and excluding bispecific monoclonal antibodies, which are directly conjugated to a radioactive isotope, for use as human anti- cancer therapeutics. | 2000-04-24 | 2000 | 4 | https://www.federalregister.gov/documents/2000/04/24/00-10166/prospective-grant-of-exclusive-license-second-generation-monoclonal-antibodies-and-humanized | https://www.govinfo.gov/content/pkg/FR-2000-04-24/pdf/00-10166.pdf | Health and Human Services Department; National Institutes of Health | 221,353 | This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in... |